Rani Therapeutics Holdings Inc To Discuss The Topline Results From The Phase 1 Part 2 Repeat Dose Study of RT-102 Call Transcript
Welcome to the Rani Therapeutics RT-102 Phase 1 Part 2 Repeat-Dose Setting conference call. At this time, all participants are in a listen-only mode. Following management's prepared remarks, we will hold a Q&A session. (Operator Instructions) As a reminder, this call is being recorded today, Tuesday, December 6, 2022.
I would now like to turn the conference call over to Lawrence Watts, Managing Director at Gilmartin Group. Please go ahead.
Thank you, operator. Joining us on the call today from Rani Therapeutics are Chief Executive Officer, Talat Imran; Chief Financial Officer, Svai Sanford; Chief Scientific Officer, Dr. Mir Hashim; and Vice President of Clinical Development, Dr. Arvinder Dhalla. please turn to slide 2.
During this conference call, management will make forward-looking statements that are subject to risks and uncertainties related to the future events and/or financial performance of the company. These forward-looking statements are subject to a number of risks, uncertainties, and
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
